Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Cancer 4Solid Tumor 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × ARRY-334543 × Clear all
NCT00278902 2020-10-14

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
96 enrolled

Advanced Cancer

NCT00637702 2020-10-08

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
31 enrolled

Advanced Cancer

NCT00710736 2020-10-06

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
29 enrolled

Advanced Cancer

NCT00833326 2020-10-06

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
27 enrolled

Advanced Cancer

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡